Selected research
Market Structure
Global Cancer Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Cancer Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Cancer Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Novartis, Merck, Mylan, Eli Lilly, Pfizer, GlaxoSmithKline and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Cancer Biopharmaceuticals market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cancer Biopharmaceuticals and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cancer Biopharmaceuticals revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Cancer Biopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.
Cancer Biopharmaceuticals Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Mylan
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
LEO Pharma
Elusys Therapeutics
Bristol-Myers Squibb
Boehringer Ingelheim
Alexion Pharmaceuticals
Agios Pharmaceuticals
Cancer Biopharmaceuticals Segment by Type
Biologics
Biosimilars
Cancer Biopharmaceuticals Segment by Application
Liquid Cancers
Solid Cancers
Cancer Biopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Cancer Biopharmaceuticals in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Biopharmaceuticals industry.
Chapter 3: Detailed analysis of Cancer Biopharmaceuticals companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Biopharmaceuticalsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilars
Applications
- Liquid Cancers
- Solid Cancers
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Mylan
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- LEO Pharma
- Elusys Therapeutics
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Agios Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Biologics
- 1.2.3 Biosimilars
- 1.3 Market Analysis by Application
- 1.3.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Liquid Cancers
- 1.3.3 Solid Cancers
- 1.4 Global Market Growth Prospects
- 1.5 Global Cancer Biopharmaceuticals Growth Trends by Region
- 1.5.1 Global Cancer Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Cancer Biopharmaceuticals Market Size by Region (2021-2026)
- 1.5.3 Cancer Biopharmaceuticals Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Cancer Biopharmaceuticals Market Dynamics
- 2.1 Cancer Biopharmaceuticals Industry Trends
- 2.2 Cancer Biopharmaceuticals Industry Drivers
- 2.3 Cancer Biopharmaceuticals Industry Opportunities and Challenges
- 2.4 Cancer Biopharmaceuticals Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Cancer Biopharmaceuticals Revenue by Company (2021-2026)
- 3.2 Global Cancer Biopharmaceuticals Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Cancer Biopharmaceuticals Key Company Head office and Area Served
- 3.4 Global Cancer Biopharmaceuticals Company, Product Type & Application
- 3.5 Global Cancer Biopharmaceuticals Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Cancer Biopharmaceuticals Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Cancer Biopharmaceuticals Players Market Share by Revenue in 2025
- 3.6.3 2025 Cancer Biopharmaceuticals Tier 1, Tier 2, and Tier 3
4 Cancer Biopharmaceuticals Market by Type
- 4.1 Global Cancer Biopharmaceuticals Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Cancer Biopharmaceuticals Market Size by Type (2021-2032)
- 4.3 Global Cancer Biopharmaceuticals Market Size Share by Type (2021-2032)
5 Cancer Biopharmaceuticals Market by Application
- 5.1 Global Cancer Biopharmaceuticals Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Cancer Biopharmaceuticals Market Size by Application (2021-2032)
- 5.3 Global Cancer Biopharmaceuticals Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Sanofi Cancer Biopharmaceuticals Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Johnson & Johnson Cancer Biopharmaceuticals Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis Cancer Biopharmaceuticals Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Merck Cancer Biopharmaceuticals Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Mylan
- 6.5.1 Mylan Company Information
- 6.5.2 Mylan Business Overview
- 6.5.3 Mylan Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Mylan Cancer Biopharmaceuticals Product Portfolio
- 6.5.5 Mylan Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Eli Lilly Cancer Biopharmaceuticals Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Pfizer
- 6.7.1 Pfizer Company Information
- 6.7.2 Pfizer Business Overview
- 6.7.3 Pfizer Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Pfizer Cancer Biopharmaceuticals Product Portfolio
- 6.7.5 Pfizer Recent Developments
- 6.8 GlaxoSmithKline
- 6.8.1 GlaxoSmithKline Company Information
- 6.8.2 GlaxoSmithKline Business Overview
- 6.8.3 GlaxoSmithKline Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 GlaxoSmithKline Cancer Biopharmaceuticals Product Portfolio
- 6.8.5 GlaxoSmithKline Recent Developments
- 6.9 AstraZeneca
- 6.9.1 AstraZeneca Company Information
- 6.9.2 AstraZeneca Business Overview
- 6.9.3 AstraZeneca Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 AstraZeneca Cancer Biopharmaceuticals Product Portfolio
- 6.9.5 AstraZeneca Recent Developments
- 6.10 LEO Pharma
- 6.10.1 LEO Pharma Company Information
- 6.10.2 LEO Pharma Business Overview
- 6.10.3 LEO Pharma Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 LEO Pharma Cancer Biopharmaceuticals Product Portfolio
- 6.10.5 LEO Pharma Recent Developments
- 6.11 Elusys Therapeutics
- 6.11.1 Elusys Therapeutics Company Information
- 6.11.2 Elusys Therapeutics Business Overview
- 6.11.3 Elusys Therapeutics Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Elusys Therapeutics Cancer Biopharmaceuticals Product Portfolio
- 6.11.5 Elusys Therapeutics Recent Developments
- 6.12 Bristol-Myers Squibb
- 6.12.1 Bristol-Myers Squibb Company Information
- 6.12.2 Bristol-Myers Squibb Business Overview
- 6.12.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Product Portfolio
- 6.12.5 Bristol-Myers Squibb Recent Developments
- 6.13 Boehringer Ingelheim
- 6.13.1 Boehringer Ingelheim Company Information
- 6.13.2 Boehringer Ingelheim Business Overview
- 6.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Product Portfolio
- 6.13.5 Boehringer Ingelheim Recent Developments
- 6.14 Alexion Pharmaceuticals
- 6.14.1 Alexion Pharmaceuticals Company Information
- 6.14.2 Alexion Pharmaceuticals Business Overview
- 6.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 6.14.5 Alexion Pharmaceuticals Recent Developments
- 6.15 Agios Pharmaceuticals
- 6.15.1 Agios Pharmaceuticals Company Information
- 6.15.2 Agios Pharmaceuticals Business Overview
- 6.15.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Product Portfolio
- 6.15.5 Agios Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Cancer Biopharmaceuticals Market Size (2021-2032)
- 7.2 North America Cancer Biopharmaceuticals Market Size by Type
- 7.2.1 North America Cancer Biopharmaceuticals Market Size by Type (2021-2026)
- 7.2.2 North America Cancer Biopharmaceuticals Market Size by Type (2027-2032)
- 7.2.3 North America Cancer Biopharmaceuticals Market Share by Type (2021-2032)
- 7.3 North America Cancer Biopharmaceuticals Market Size by Application
- 7.3.1 North America Cancer Biopharmaceuticals Market Size by Application (2021-2026)
- 7.3.2 North America Cancer Biopharmaceuticals Market Size by Application (2027-2032)
- 7.3.3 North America Cancer Biopharmaceuticals Market Share by Application (2021-2032)
- 7.4 North America Cancer Biopharmaceuticals Market Size by Country
- 7.4.1 North America Cancer Biopharmaceuticals Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 7.4.3 North America Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 7.4.4 North America Cancer Biopharmaceuticals Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Cancer Biopharmaceuticals Market Size (2021-2032)
- 8.2 Europe Cancer Biopharmaceuticals Market Size by Type
- 8.2.1 Europe Cancer Biopharmaceuticals Market Size by Type (2021-2026)
- 8.2.2 Europe Cancer Biopharmaceuticals Market Size by Type (2027-2032)
- 8.2.3 Europe Cancer Biopharmaceuticals Market Share by Type (2021-2032)
- 8.3 Europe Cancer Biopharmaceuticals Market Size by Application
- 8.3.1 Europe Cancer Biopharmaceuticals Market Size by Application (2021-2026)
- 8.3.2 Europe Cancer Biopharmaceuticals Market Size by Application (2027-2032)
- 8.3.3 Europe Cancer Biopharmaceuticals Market Share by Application (2021-2032)
- 8.4 Europe Cancer Biopharmaceuticals Market Size by Country
- 8.4.1 Europe Cancer Biopharmaceuticals Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 8.4.3 Europe Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 8.4.4 Europe Cancer Biopharmaceuticals Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Cancer Biopharmaceuticals Market Size (2021-2032)
- 9.2 China Cancer Biopharmaceuticals Market Size by Type
- 9.2.1 China Cancer Biopharmaceuticals Market Size by Type (2021-2026)
- 9.2.2 China Cancer Biopharmaceuticals Market Size by Type (2027-2032)
- 9.2.3 China Cancer Biopharmaceuticals Market Share by Type (2021-2032)
- 9.3 China Cancer Biopharmaceuticals Market Size by Application
- 9.3.1 China Cancer Biopharmaceuticals Market Size by Application (2021-2026)
- 9.3.2 China Cancer Biopharmaceuticals Market Size by Application (2027-2032)
- 9.3.3 China Cancer Biopharmaceuticals Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Cancer Biopharmaceuticals Market Size (2021-2032)
- 10.2 Asia Cancer Biopharmaceuticals Market Size by Type
- 10.2.1 Asia Cancer Biopharmaceuticals Market Size by Type (2021-2026)
- 10.2.2 Asia Cancer Biopharmaceuticals Market Size by Type (2027-2032)
- 10.2.3 Asia Cancer Biopharmaceuticals Market Share by Type (2021-2032)
- 10.3 Asia Cancer Biopharmaceuticals Market Size by Application
- 10.3.1 Asia Cancer Biopharmaceuticals Market Size by Application (2021-2026)
- 10.3.2 Asia Cancer Biopharmaceuticals Market Size by Application (2027-2032)
- 10.3.3 Asia Cancer Biopharmaceuticals Market Share by Application (2021-2032)
- 10.4 Asia Cancer Biopharmaceuticals Market Size by Country
- 10.4.1 Asia Cancer Biopharmaceuticals Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 10.4.3 Asia Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 10.4.4 Asia Cancer Biopharmaceuticals Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Type
- 11.2.1 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Cancer Biopharmaceuticals Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Application
- 11.3.1 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Cancer Biopharmaceuticals Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Country
- 11.4.1 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Cancer Biopharmaceuticals Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Cancer Biopharmaceuticals Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst